COMP <GO>
PRME vs ODTX // REVENUE GROWTH (YOY)
Prime Medicine Inc. (NASDAQ) VS. Odyssey Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PRME 1
— ODTX 1
■ METRIC PARITY
LAST: $4.72 (-9.92%) • MKT CAP: $950.4M
revenue-growth
55.30%
LAST: $19.54 (-1.46%) • MKT CAP: $953.0M
revenue-growth
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PRME VS. ODTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PRME | ODTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -17.58% | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 55.30% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 66.3 | 50.8 | +15.50 | PRME | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $950.4M | $953.0M | -$2.6M | ODTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PRME REV | ODTX REV | PRME GROSS % | ODTX GROSS % | PRME FCF | ODTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.6M | $0 | — | — | -$167.1M | — |
| FY 2024 | $3.0M | — | — | — | -$130.2M | — |
| FY 2023 | $0 | — | — | — | -$165.4M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PRME // BETA —
ODTX // BETA —